Newland Pharmaceutical Co., Ltd. (SHE:301277)
China
· Delayed Price · Currency is CNY 12.31
-0.08 (-0.65%)
Mar 9, 2026, 4:00 PM EDT
Newland Pharmaceutical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Market Capitalization | 4,889 | 3,873 | 4,163 | 3,850 | - | - | Upgrade
|
| Market Cap Growth | 19.58% | -6.96% | 8.12% | - | - | - | Upgrade
|
| Enterprise Value | 4,180 | 3,072 | 3,378 | 3,956 | - | - | Upgrade
|
| Last Close Price | 12.47 | 9.64 | 10.19 | 9.28 | - | - | Upgrade
|
| PE Ratio | 39.51 | 22.31 | 26.19 | 29.10 | - | - | Upgrade
|
| PS Ratio | 7.29 | 5.33 | 6.39 | 6.14 | - | - | Upgrade
|
| PB Ratio | 3.21 | 2.51 | 2.87 | 2.83 | - | - | Upgrade
|
| P/TBV Ratio | 3.32 | 2.57 | 2.95 | 2.92 | - | - | Upgrade
|
| P/FCF Ratio | 296.36 | 242.50 | 25.55 | 452.81 | - | - | Upgrade
|
| P/OCF Ratio | 36.17 | 30.56 | 16.04 | 46.47 | - | - | Upgrade
|
| EV/Sales Ratio | 6.23 | 4.23 | 5.19 | 6.31 | - | - | Upgrade
|
| EV/EBITDA Ratio | 24.84 | 14.22 | 17.72 | 23.63 | - | - | Upgrade
|
| EV/EBIT Ratio | 33.16 | 16.98 | 20.87 | 27.22 | - | - | Upgrade
|
| EV/FCF Ratio | 253.36 | 192.33 | 20.73 | 465.21 | - | - | Upgrade
|
| Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.31 | 0.35 | Upgrade
|
| Debt / EBITDA Ratio | 0.04 | 0.01 | 0.01 | 0.03 | 0.80 | 0.69 | Upgrade
|
| Debt / FCF Ratio | 0.37 | 0.19 | 0.02 | 0.67 | 5.34 | 3.57 | Upgrade
|
| Net Debt / Equity Ratio | -0.47 | -0.52 | -0.59 | -0.55 | 0.21 | 0.24 | Upgrade
|
| Net Debt / EBITDA Ratio | -4.28 | -3.72 | -4.49 | -4.46 | 0.53 | 0.46 | Upgrade
|
| Net Debt / FCF Ratio | -43.02 | -50.32 | -5.26 | -87.83 | 3.53 | 2.38 | Upgrade
|
| Asset Turnover | 0.39 | 0.42 | 0.41 | 0.57 | 0.86 | 0.90 | Upgrade
|
| Inventory Turnover | 7.10 | 11.50 | 9.30 | 6.12 | 4.81 | 5.81 | Upgrade
|
| Quick Ratio | 5.73 | 5.26 | 7.89 | 7.14 | 1.42 | 1.22 | Upgrade
|
| Current Ratio | 6.30 | 5.51 | 8.29 | 7.61 | 1.82 | 1.51 | Upgrade
|
| Return on Equity (ROE) | 8.07% | 11.56% | 11.19% | 14.92% | 31.91% | 46.93% | Upgrade
|
| Return on Assets (ROA) | 4.52% | 6.61% | 6.44% | 8.25% | 14.32% | 18.59% | Upgrade
|
| Return on Invested Capital (ROIC) | 13.21% | 23.81% | 23.31% | 24.30% | 27.06% | 41.41% | Upgrade
|
| Return on Capital Employed (ROCE) | 8.00% | 11.30% | 11.00% | 10.50% | 30.50% | 41.50% | Upgrade
|
| Earnings Yield | 2.53% | 4.48% | 3.82% | 3.44% | - | - | Upgrade
|
| FCF Yield | 0.34% | 0.41% | 3.91% | 0.22% | - | - | Upgrade
|
| Dividend Yield | 2.32% | 2.96% | 2.00% | 1.83% | - | - | Upgrade
|
| Payout Ratio | 90.55% | 46.08% | 41.94% | 5.12% | 31.92% | 45.98% | Upgrade
|
| Buyback Yield / Dilution | -0.39% | -0.39% | -29.52% | -2.59% | -0.64% | -0.34% | Upgrade
|
| Total Shareholder Return | 1.93% | 2.57% | -27.51% | -0.75% | -0.64% | -0.34% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.